Despite Recession Concerns, Six in Ten Healthcare and Life Sciences Investors Plan to Increase M&A Activity in 2023
Amid a challenging economic environment defined by persistent inflation, rising interest rates, recessionary concerns and falling equity values increasing uncertainty, healthcare and life sciences (HCLS) investors are poised to forge ahead with 60% of respondents indicating they plan to increase their M&A activity in 2023 according to new findings from the 2023 KPMG Healthcare and Life Sciences Investment Outlook.
"2022 is a story of both tailwinds and headwinds," said Ash Shehata, KPMG National Sector Leader Healthcare and Life Sciences. "Hospital systems are dealing with rising labor and supply costs while biopharma and medical device companies have been exposed to supply chain, logistics, and labor issues that slow down production. Now is the time for HCLS leaders to adjust their strategies to build durability and resilience within their companies."